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To the Editor: Prisons represent 
a crucial setting for tuberculosis (TB) 
control. Worldwide, reported TB rates 
for correctional system populations 
have been 10–100× higher than rates 
for the local civilian populations, and 
TB outbreaks with a high number of 
TB multidrug-resistant cases have 
been documented (1,2). Prisons 
are known as social and sanitary 
pathology reservoirs in which TB 
is often associated with chronic 
infectious diseases caused by HIV, 
hepatitis B virus (HBV), or hepatitis C 
virus (HCV) (2).
HCV prevalence among inmates 
is 30%–40% (range 2%–58%), which 
is higher than that in the general 
population and is related to injection 
drug use (3). For these reasons, 
effective anti-HCV therapeutic 
approaches are recommended by 
national and international guidelines 
for decreasing illness, death rates, and 
reservoirs of infection in prisons (4,5).
The standard of care for 
patients with chronic hepatitis C 
infection is represented by pegylated 
interferon-α (Peg-IFN) and ribavirin. 
These drugs determine complex 
antiviral, immunomodulatory, and 
antiproliferative actions, which can 
cause serious side effects such as 
leukopenia/neutropenia and alterations 
in the cytokine network (3). Although 
severe cellular immunodefi ciency can 
often facilitate the development of 
many infections, only 4 clinical cases 
of TB in patients undergoing HCV 
antiviral therapy have been described 
in the literature (6–8), and only 1 of 
these was clearly described as a TB 
reactivation (7).
We describe a case of pulmonary 
TB reactivation during therapy with 
Peg-IFN and ribavirin in a 44-year-
old white male inmate, affected by 
genotype 1b/4a chronic hepatitis 
C. After prison admission in 2009, 
he underwent routine screening 
tests for infectious diseases, which 
indicated HCV antibody, HBV surface 
antibody, HBV core IgG antibody, and 
tuberculin skin test positivity. Results 
of chest radiograph and HIV screening 
were negative.
His previous history involved 
injection drug use, smoking, 
and alcohol consumption. Anti-
HCV therapy of directly observed 
administration of Peg-INF 
α-2a (180 μg/wk) and ribavirin 
(1,200 mg/d) was started. During 
therapy, the patient had only mild 
musculoskeletal pain and temporary 
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irritability. During the 12th week of 
treatment, HCV-RNA decreased by 
1 log10; therefore, the ribavirin dose 
was increased to 1,600 mg per day. 
Even after the therapy modifi cation, 
no virologic suppression was found. 
Although during the 33rd week of 
therapy the patient had weakness, 
cough, and 2 episodes of hemoptysis, 
the results of a physical examination 
were unremarkable. Therapy was 
immediately discontinued. Sputum 
specimens collected on 3 consecutive 
days were positive for acid-fast 
bacilli. Nucleic acid amplifi cation 
assays and cultures performed on 
mycobacteria growth indicator tube 
(Bactec MGIT; Becton Dickinson, 
Franklin Lakes, NJ, USA) and 
on Lowenstein-Jensen medium 
were positive for Mycobacterium 
tuberculosis isolates that later showed 
sensitivity to streptomycin, isoniazid, 
rifampin, and ethambutol.
The patient was isolated at the 
Institute of Respiratory Diseases, 
University of Sassari–Faculty of 
Medicine, Sassari, Italy. A chest 
radiograph showed opacity in the 
upper right lung, and a high-resolution 
computed tomography scan (Figure) 
showed multiple lesions that were 
considered compatible with TB. CD4+ 
cell count (52.4%; 669 cells/mm3) was 
within reference range.
TB treatment with rifampin, 
isoniazid, pyrazinamide, and 
ethambutol with pyridoxine was 
started. After 4 weeks of therapy, 3 
sputum specimens were negative for 
acid-fast bacilli, but a bacterial culture 
was still positive; mycobacteria 
indicator growth tube culture was 
negative after 5 weeks.
The interaction process between 
the IFN-α/β system and M. tuberculosis 
is not well known; nevertheless, Peg- 
IFN, alone and in combination with 
ribavirin, is considered poten-tially 
immunosuppressive (4,9). Immuno-
defi ciency caused by Peg-IFNs and 
ribavirin may cause lower leukopenia/
lymphopenia values than expected 
during anti-HCV treatment and may 
also lower CD4+ cell count and 
function (10).
In the patient reported here, 
CD4+ cell count was within the 
reference range, and lung TB with 
excavations developed after 34 weeks 
of therapy. Before TB diagnosis, the 
patient had not shown any signs or 
symptoms of other infections and had 
not mentioned serious adverse effects 
from Peg-IFN and ribavirin treatment. 
However, the initial symptoms of 
TB and the common side effects 
of Peg-IFN therapy can be similar, 
which could have led to a delay in the 
diagnosis of TB.
In conclusion, even if only a few 
cases of active TB have been reported 
in the literature, it is well known 
that standard anti-HCV treatment 
increases the risk for infections. A high 
proportion of patients with positive 
purifi ed protein derivative results, 
isolation of >30% of multidrug-
resistant strains of M. tuberculosis, 
and high prevalence of HCV antibody 
are concomitant among inmates. 
These data, together with current 
recommendations for increasing use of 
Peg-IFN and ribavirin in marginalized 
populations in correctional facilities, 
show the need to consider TB risk 
before starting HCV antiviral therapy. 
The management of simultaneous 
HCV and M. tuberculosis infections in 
prisons presents particular diffi culties 
and pitfalls to overcome. In prisons, 
the clinical history of inmates should 
be carefully evaluated, a tuberculin 
skin test or Quantiferon TB in Tube 
test (Cellestis, Melbourne, Australia) 
should be performed, and, if those 
results are positive, a chest radiograph 
should be taken. Before receiving 
Peg-IFN, purifi ed protein derivative–
positive patients should receive anti-
TB chemoprophylaxis. The case 
described here underscores the need 
for a careful and multidisciplinary 
evaluation of inmate patients for latent 
TB before administration of Peg-IFN 
and ribavirin therapy, thus avoiding 
reactivation.
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Figure. Computed tomography image of chest of patient with tuberculosis after anti–
hepatitis C virus therapy. A parenchymal distortion 32 mm in diameter is shown in the 
upper right lung with initial central excavation 10 mm in diameter. Similar lesions 8 mm in 
diameter without central excavation are shown in the upper left lung.
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Defi cient Reporting 
in Avian Infl uenza 
Surveillance, Mali
To the Editor: In response to 
infl uenza outbreaks caused by highly 
pathogenic avian infl uenza virus 
(HPAIV) throughout western Africa 
as of 2006, the National Veterinary 
Epidemiologic Surveillance Network 
of Mali (EPIVET-Mali) started 
conducting domestic and wild bird 
surveillance. No HPAI outbreaks were 
reported to the World Organisation 
for Animal Health. An evaluation 
survey conducted in 2009 enabled 
identifi cation and correction of some 
weaknesses in the organization 
and functioning of the network (1). 
However, no attempt was made to 
assess how much information on 
bird health in backyard poultry farms 
(which account for ≈95% of the total 
poultry population in Mali) actually 
reached EPIVET-Mali veterinarians 
and technicians. Therefore, we 
quantifi ed reporting of clinical signs 
of avian diseases, especially those 
suggesting HPAI, by poultry owners 
in Mali.
We used a pilot-tested stan-
dardized quantitative and qualitative 
questionnaire to conduct face-to-
face interviews in 32 randomly 
selected villages in the southern half 
of Mali (which accounts for 98% 
of the poultry population). In each 
village, we conducted interviews 
in 4 randomly chosen households. 
No eligibility criteria were used for 
household selection because all village 
households had poultry. Interviews 
were repeated 6 times (approximately 
every 3 months) during November 
2009–February 2011 in the same 
villages and whenever possible in the 
same households. If it was not possible 
to repeat an interview in a previously 
interviewed household (absence of 
the household chief), the neighboring 
household was interviewed.
For each household, data 
were collected on number of sick 
and dead birds in the previous 3 
months, clinical signs observed, and 
their notifi cation or lack thereof to 
veterinary authorities. Households 
in which birds showed >3 of the 
following clinical signs (diarrhea, 
respiratory disorder, nervous signs, 
cyanosis of the combs or wattles, and 
mortality rate >50%) were considered 
as having clinical signs suggesting 
HPAI. The study was approved by 
the Direction Nationale des Services 
Vétérinaires and traditional authorities 
in all 32 villages, and oral consent was 
obtained from the poultry owners 
before interviews.
A total of 110–128 households 
were investigated at each study interval, 
depending on village accessibility and 
presence or absence of household 
chiefs (Table). We conducted 738 
household investigations in 152 
households (80 households were 
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